Champions Oncology Inc.
9.45
0.28 (3.05%)
At close: Jan 14, 2025, 3:59 PM
9.67
2.33%
After-hours Jan 14, 2025, 04:00 PM EST
undefined%
Bid 9.11
Market Cap 130.59M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -0.05
PE Ratio (ttm) -189
Forward PE n/a
Analyst Strong Buy
Ask 10.52
Volume 29,983
Avg. Volume (20D) 43,268
Open 9.18
Previous Close 9.17
Day's Range 9.13 - 9.67
52-Week Range 3.60 - 10.90
Beta undefined

About CSBR

Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune...

Industry Biotechnology
Sector Healthcare
IPO Date Feb 2, 2007
Employees 210
Stock Exchange NASDAQ
Ticker Symbol CSBR

Analyst Forecast

According to 1 analyst ratings, the average rating for CSBR stock is "Strong Buy." The 12-month stock price forecast is $8, which is a decrease of -15.34% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts

Next Earnings Release

Champions Oncology Inc. is scheduled to release its earnings on Mar 11, 2025, during market hours.
Analysts project revenue of $12.93M, reflecting a 7.58% YoY growth and earnings per share of -0.01, making a -93.75% decrease YoY.
1 month ago · Source
+12.09%
Champions Oncology shares are trading higher after... Unlock content with Pro Subscription
4 months ago · Source
+9.58%
Champions Oncology shares are trading higher after the company reported better-than-expected Q1 financial results. Also, Craig-Hallum upgraded the stock from Hold to Buy and maintained its $6 price target.